daptomycin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Late Effects of Surgery

Conditions

Late Effects of Surgery, Staphylococcus Aureus, Surgical Site Infection

Trial Timeline

Jul 1, 2008 → Oct 1, 2010

NCT ID

NCT00701636

About daptomycin

daptomycin is a phase 3 stage product being developed by Merck for Late Effects of Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT00701636. Target conditions include Late Effects of Surgery, Staphylococcus Aureus, Surgical Site Infection.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01025271	Pre-clinical	Terminated	May 1, 2010	May 1, 2011	Meningitis
NCT01019395	Phase 1	Completed	Jan 5, 2010	Mar 20, 2012	Gram Positive Bacterial Infection
NCT01012089	Pre-clinical	Completed	Nov 1, 2009	Apr 1, 2014	Chronic Kidney Disease
NCT00701636	Phase 3	Completed	Jul 1, 2008	Oct 1, 2010	Late Effects of Surgery
NCT00679835	Phase 1	Completed	Jun 3, 2008	Nov 20, 2008	Gram Positive Infection
NCT00490737	Phase 1	Completed	Aug 12, 2007	May 12, 2008	End-Stage Renal Disease
NCT00467272	Phase 2	Completed	Mar 1, 2007	Sep 1, 2012	Bloodstream Infection
NCT00663403	Approved	Completed	Feb 1, 2007	Apr 1, 2009	Critically Ill
NCT00507247	Phase 2	Completed	May 1, 2006	Sep 1, 2012	Staphylococcus Aureus
NCT00136292	Phase 1	Completed	Aug 24, 2005	Aug 9, 2006	Gram-positive Bacterial Infections
NCT00651131	Approved	Terminated	Jun 1, 2004	Mar 1, 2005	Wound Infections
NCT00055198	Phase 3	Terminated	Dec 19, 2002	Jan 26, 2004	Gram-Positive Bacterial Infections
NCT00093067	Phase 3	Completed	Mar 1, 2002	Feb 1, 2005	Bacterial Endocarditis
NCT00540072	Phase 3	Completed	Jul 30, 2001	Feb 27, 2002	Pneumonia, Bacterial
NCT00538694	Phase 3	Completed	Oct 31, 2000	Sep 30, 2001	Pneumonia, Bacterial

Competing Products

20 competing products in Late Effects of Surgery

See all competitors

Product	Company	Stage	Hype Score
CLS-AX + Anti-VEGF	Clearside Biomedical	Phase 1/2	33
CLS-AX + Aflibercept	Clearside Biomedical	Phase 2	44
Eylea + ALT-L9	Alteogen	Phase 1	33
FYB203 2 mg (0.05 mL of 40 mg/mL)	Formycon AG	Approved	77
FYB201 0.5 mg (0.05 mL of 10 mg/mL)	Formycon AG	Approved	77
AL001 + Placebo	Alector	Phase 2	44
89Zr-DFO-AP-101	Eli Lilly	Phase 1	33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)	Unity Biotechnology	Phase 2	44
Sarpogrelate Sustained Release/Aspirin + Aspirin	Yuhan	Approved	85
DS-7080a + Ranibizumab	Daiichi Sankyo	Phase 1	33
olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary	Daiichi Sankyo	Phase 3	77
Fovista® + bevacizumab + ranibizumab + aflibercept	Astellas Pharma	Phase 2	52
MA09-hRPE	Astellas Pharma	Pre-clinical	23
volociximab	Astellas Pharma	Phase 1	33
Avacincaptad Pegol	Astellas Pharma	Phase 1	33
Avacincaptad Pegol + Avastin + Lucentis + Eylea	Astellas Pharma	Phase 2	52
Avacincaptad Pegol	Astellas Pharma	Phase 1	33
E10030 + ranibizumab + E10030 sham intravitreal injection	Astellas Pharma	Phase 3	77
E10030	Astellas Pharma	Phase 1	33
Basiliximab, Tacrolimus, MMF, Prednisolon + Basiliximab, Tacrolimus, MMF + Tacrolimus, MMF, rATG	Astellas Pharma	Approved	85

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved